A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Exclusion Criteria

• •1. Participants with clinically significant pre-existing cardiac impairment.
• •2. Participants homozygous for the ABCG2 (BCRP) c.421C greater than (\>) 1 A polymorphism will be excluded from the study until the safety of a minimum of the first 3 dose levels has been characterized and the sponsor confirms that such participants can be enrolled at doses that are at least 3-fold lower than the most recently determined safe and tolerable dose among at least 3 dose limiting toxicities (DLT)-evaluable non-homozygous participants.
• •3. Participants with known active central nervous system (CNS) lesions are excluded. Systemic antineoplastic therapy or investigational agents within 21 days before the first dose of study drug.
• •4. Radiotherapy within 14 days before the first dose of study drug is not allowed except for limited field radiotherapy for palliative bone pain.
• •5. For participants where tumor biopsies are required or requested:
• •* Any known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
• •* Ongoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel \[Plavix®\], heparin, or warfarin).
• •6. Major surgery within 28 days before the first dose of MLN7243.
• •7. Life-threatening illness unrelated to cancer.
• •8. Any evidence of active infection or antibiotic therapy within 14 days before the first dose of MLN7243.
• •9. Known human immunodeficiency virus (HIV) positivity or AIDS-related illness, hepatitis B virus, and hepatitis C virus.
• •10. Participants whose weight is less than (\<) 40 kilogram (kg).
• •11. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease.
• •12. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.